CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene, for patients with bladder cancer. Co. is at a clinical stage and does not project to generate significant revenues if and until the U.S. Food and Drug Administration (FDA) approves its primary asset, cretostimogene. We show 6 historical shares outstanding datapoints in our CGON shares outstanding history coverage, used to compute CGON market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CGON market cap history over the course of time is important for investors
interested in comparing CGON's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CGON versus a peer is one thing; comparing
CGON market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CGON can fluctuate over the course of history.
With this page we aim to empower investors researching CGON by allowing them to research the CGON market cap history. |
Free CGON Email Alerts:
Video: The Importance of Market Cap
